FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3033991667> ?p ?o ?g. }

• W3033991667 abstract "Abstract Background and Aims Although few randomized controlled trials have been able to demonstrate benefits of single treatments in improving outcomes of patients undergoing hemodialysis (HD), the last decades have witnessed significant therapeutic advances. This relates both to the HD treatment itself and to the management of patient complications. We here evaluated temporal changes in the use of evidence-based treatments and survival rates in incident HD patients. Method We included all patients initiating HD in Sweden between 2006-2015 and followed them until the end of 2017. Data were linked to national registries to retrieve information on date of death, cardiovascular events, comorbidity, and drug prescriptions. We first evaluated trends in the use of different HD related therapies and selected key therapeutic targets and medications in 2-year blocks. We then evaluated the incidence of death and major cardiovascular events (MACE) within one and two years from start of dialysis through standardized incidence rates via logistic regression models to account for differences in patient characteristics over time. Via Cox regression models, we explored whether adjustment for implementation of evidence-based treatments (e.g. hemodiafiltration (HDF), frequent HD, working fistula, drugs to control CKD-MBD, anemia) modified the observed survival and MACE risks. Finally, survival trends were also compared against an age-sex-calendar year-matched general Swedish population using standardized incidence ratios. Results We identified 6,612 patients starting HD in Sweden during the study period. There was no difference in mean age or proportion of women over time, but body mass index, serum parathyroid hormone levels and the proportion of patients with cerebrovascular disease, atrial fibrillation and cancer increased. Conversely, mean serum hemoglobin, phosphate and albumin values decreased over time. The proportion of patients who underwent HDF, had more than three HD sessions/week, and had a working fistula increased progressively, as well as the use of phosphate binders (particularly non-calcium), cinacalcet, and vitamin D3. After standardization for differences in demography and comorbidities, the one-year risk of mortality or MACE risk decreased by 7% and 16%, respectively, in 2014/15 compared to 2006/07. Similarly, the two-year risk of death or MACE decreased by 16 and 21%. In multivariable Cox models, we explored the linear association between calendar year blocks and study outcomes. Per 2-year period, the risk of death within one year decreased by 6% (HR 0.94, 95% CI 0.92-1.00), and of MACE by 5% (0.94, 95% CI 0.92-0.98). Adjustment for changes in the evidence-based treatments over time abrogated these associations (HR 1.00, 95% CI 0.91-1.09 for death and 1.00, 95% CI 0.94-1.06 for MACE). Similar results were obtained for 2-year outcomes. Compared with the general population, the one-year risk of death for a HD patient was 6 times higher in 2006/2007 [standardized incidence rate ratio, SIR 6.05 (5.30–6.91)], but decreased to 5.5 times higher in 2014/15 [SIR 5.57 (4.82–6.44)], corresponding to a SIR reduction of 8%. Conclusion In patients initiating HD therapy in Sweden, there has been a gradual implementation of new and established evidence-based treatments during the last 10 years, which was associated with a parallel reduction in the risk of death and MACE." @default.
• W3033991667 created "2020-06-12" @default.
• W3033991667 creator A5025205269 @default.
• W3033991667 creator A5038261777 @default.
• W3033991667 creator A5040457003 @default.
• W3033991667 creator A5053537325 @default.
• W3033991667 creator A5083454874 @default.
• W3033991667 date "2020-06-01" @default.
• W3033991667 modified "2023-10-04" @default.
• W3033991667 title "P1437RELATIONS BETWEEN IMPLEMENTATIONS OF EVIDENCE-BASED TREATMENTS AND IMPROVED OUTCOMES IN PATIENTS STARTING HEMODIALYSIS DURING THE LAST 10 YEARS: EXPERIENCES FROM THE SWEDISH RENAL REGISTRY 2006-2015" @default.
• W3033991667 doi "https://doi.org/10.1093/ndt/gfaa142.p1437" @default.
• W3033991667 hasPublicationYear "2020" @default.
• W3033991667 type Work @default.
• W3033991667 sameAs 3033991667 @default.
• W3033991667 citedByCount "0" @default.
• W3033991667 crossrefType "journal-article" @default.
• W3033991667 hasAuthorship W3033991667A5025205269 @default.
• W3033991667 hasAuthorship W3033991667A5038261777 @default.
• W3033991667 hasAuthorship W3033991667A5040457003 @default.
• W3033991667 hasAuthorship W3033991667A5053537325 @default.
• W3033991667 hasAuthorship W3033991667A5083454874 @default.
• W3033991667 hasBestOaLocation W30339916671 @default.
• W3033991667 hasConcept C120665830 @default.
• W3033991667 hasConcept C121332964 @default.
• W3033991667 hasConcept C126322002 @default.
• W3033991667 hasConcept C177713679 @default.
• W3033991667 hasConcept C2426938 @default.
• W3033991667 hasConcept C2777288759 @default.
• W3033991667 hasConcept C2778063415 @default.
• W3033991667 hasConcept C2778248108 @default.
• W3033991667 hasConcept C2779159551 @default.
• W3033991667 hasConcept C2779978075 @default.
• W3033991667 hasConcept C2780739214 @default.
• W3033991667 hasConcept C2781404941 @default.
• W3033991667 hasConcept C2908647359 @default.
• W3033991667 hasConcept C45393284 @default.
• W3033991667 hasConcept C500558357 @default.
• W3033991667 hasConcept C50382708 @default.
• W3033991667 hasConcept C61511704 @default.
• W3033991667 hasConcept C71924100 @default.
• W3033991667 hasConcept C72563966 @default.
• W3033991667 hasConcept C88879693 @default.
• W3033991667 hasConcept C98274493 @default.
• W3033991667 hasConcept C99454951 @default.
• W3033991667 hasConceptScore W3033991667C120665830 @default.
• W3033991667 hasConceptScore W3033991667C121332964 @default.
• W3033991667 hasConceptScore W3033991667C126322002 @default.
• W3033991667 hasConceptScore W3033991667C177713679 @default.
• W3033991667 hasConceptScore W3033991667C2426938 @default.
• W3033991667 hasConceptScore W3033991667C2777288759 @default.
• W3033991667 hasConceptScore W3033991667C2778063415 @default.
• W3033991667 hasConceptScore W3033991667C2778248108 @default.
• W3033991667 hasConceptScore W3033991667C2779159551 @default.
• W3033991667 hasConceptScore W3033991667C2779978075 @default.
• W3033991667 hasConceptScore W3033991667C2780739214 @default.
• W3033991667 hasConceptScore W3033991667C2781404941 @default.
• W3033991667 hasConceptScore W3033991667C2908647359 @default.
• W3033991667 hasConceptScore W3033991667C45393284 @default.
• W3033991667 hasConceptScore W3033991667C500558357 @default.
• W3033991667 hasConceptScore W3033991667C50382708 @default.
• W3033991667 hasConceptScore W3033991667C61511704 @default.
• W3033991667 hasConceptScore W3033991667C71924100 @default.
• W3033991667 hasConceptScore W3033991667C72563966 @default.
• W3033991667 hasConceptScore W3033991667C88879693 @default.
• W3033991667 hasConceptScore W3033991667C98274493 @default.
• W3033991667 hasConceptScore W3033991667C99454951 @default.
• W3033991667 hasLocation W30339916671 @default.
• W3033991667 hasOpenAccess W3033991667 @default.
• W3033991667 hasPrimaryLocation W30339916671 @default.
• W3033991667 hasRelatedWork W11030815 @default.
• W3033991667 hasRelatedWork W13410599 @default.
• W3033991667 hasRelatedWork W15964608 @default.
• W3033991667 hasRelatedWork W16383679 @default.
• W3033991667 hasRelatedWork W17784472 @default.
• W3033991667 hasRelatedWork W20208395 @default.
• W3033991667 hasRelatedWork W3079015 @default.
• W3033991667 hasRelatedWork W7756903 @default.
• W3033991667 hasRelatedWork W9450651 @default.
• W3033991667 hasRelatedWork W13449152 @default.
• W3033991667 isParatext "false" @default.
• W3033991667 isRetracted "false" @default.
• W3033991667 magId "3033991667" @default.
• W3033991667 workType "article" @default.